JP2023106599A5 - - Google Patents

Download PDF

Info

Publication number
JP2023106599A5
JP2023106599A5 JP2023090878A JP2023090878A JP2023106599A5 JP 2023106599 A5 JP2023106599 A5 JP 2023106599A5 JP 2023090878 A JP2023090878 A JP 2023090878A JP 2023090878 A JP2023090878 A JP 2023090878A JP 2023106599 A5 JP2023106599 A5 JP 2023106599A5
Authority
JP
Japan
Prior art keywords
seq
mhc
pharmaceutical composition
use according
encoded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023090878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023106599A (ja
Filing date
Publication date
Priority claimed from JP2020502551A external-priority patent/JP7457642B2/ja
Application filed filed Critical
Publication of JP2023106599A publication Critical patent/JP2023106599A/ja
Publication of JP2023106599A5 publication Critical patent/JP2023106599A5/ja
Priority to JP2025031867A priority Critical patent/JP2025084910A/ja
Pending legal-status Critical Current

Links

JP2023090878A 2017-04-03 2023-06-01 タンパク質抗原およびその使用 Pending JP2023106599A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031867A JP2025084910A (ja) 2017-04-03 2025-02-28 タンパク質抗原およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762480596P 2017-04-03 2017-04-03
US201762480597P 2017-04-03 2017-04-03
US201762480593P 2017-04-03 2017-04-03
US62/480,596 2017-04-03
US62/480,597 2017-04-03
US62/480,593 2017-04-03
JP2020502551A JP7457642B2 (ja) 2017-04-03 2018-04-03 タンパク質抗原およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020502551A Division JP7457642B2 (ja) 2017-04-03 2018-04-03 タンパク質抗原およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031867A Division JP2025084910A (ja) 2017-04-03 2025-02-28 タンパク質抗原およびその使用

Publications (2)

Publication Number Publication Date
JP2023106599A JP2023106599A (ja) 2023-08-01
JP2023106599A5 true JP2023106599A5 (enExample) 2024-03-12

Family

ID=62063214

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020502551A Active JP7457642B2 (ja) 2017-04-03 2018-04-03 タンパク質抗原およびその使用
JP2023090878A Pending JP2023106599A (ja) 2017-04-03 2023-06-01 タンパク質抗原およびその使用
JP2025031867A Pending JP2025084910A (ja) 2017-04-03 2025-02-28 タンパク質抗原およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020502551A Active JP7457642B2 (ja) 2017-04-03 2018-04-03 タンパク質抗原およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031867A Pending JP2025084910A (ja) 2017-04-03 2025-02-28 タンパク質抗原およびその使用

Country Status (6)

Country Link
US (1) US12303561B2 (enExample)
EP (1) EP3606550A2 (enExample)
JP (3) JP7457642B2 (enExample)
CN (2) CN118370809A (enExample)
CA (1) CA3058807A1 (enExample)
WO (1) WO2018187356A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
RS65430B1 (sr) 2016-03-16 2024-05-31 Amal Therapeutics Sa Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
KR20240149976A (ko) 2017-04-04 2024-10-15 바린투스 바이오테라퓨틱스 노쓰 아메리카, 인크. 펩티드-기반 백신, 그의 제조 방법, 및 면역 반응을 유도하기 위한 그의 용도
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
KR20220035457A (ko) * 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
CN113493494B (zh) * 2020-03-20 2022-08-16 上海交通大学医学院附属瑞金医院 Eb病毒balf3蛋白的抗原表位
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
EP4293038A4 (en) * 2021-02-10 2025-06-18 Xiamen University PEPTIDE EPITOPE AND ANTIBODY FOR PREVENTING AND TREATING EB VIRUS INFECTION AND ASSOCIATED DISEASES
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN114128714B (zh) * 2021-12-07 2023-05-02 昆明学院 一种提高葡萄耐铝毒胁迫的药剂及处理方法
WO2023111306A1 (en) * 2021-12-17 2023-06-22 Evaxion Biotech A/S Personalized cancer therapy targeting normally non-expressed sequences
EP4626903A1 (en) * 2022-12-02 2025-10-08 Seattle Project Corp. Compositions and methods of use thereof

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
SG52492A1 (en) 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
CA2157510A1 (en) 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
FR2753627B1 (fr) 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AU5898400A (en) 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
JP2003509035A (ja) * 1999-09-16 2003-03-11 ザイコス インク. ポリエピトープポリペプチドをコードする核酸
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1250351B1 (en) 2000-01-28 2005-11-30 Statens Serum Institut Methods to identify ctl epitopes of hiv
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
BR0111956A (pt) * 2000-06-26 2003-05-13 Stressgen Biotechnologies Corp Tratamento do vìrus do papiloma humano
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
EP1911461B1 (en) * 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
EP1338606A1 (en) 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
JPWO2003090788A1 (ja) 2002-04-24 2005-08-25 株式会社ギンコバイオメディカル研究所 Th2サイトカイン関連アレルギー疾患を治療および/または予防するためのデコイ、GATA3変異体蛋白質、ならびにこれらを含む医薬組成物
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
JP2006503914A (ja) * 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
EP1660686B1 (en) * 2003-09-05 2012-05-09 Genencor International, Inc. Hpv cd8+ t-cell epitopes
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
GB0413688D0 (en) 2004-06-18 2004-07-21 Novartis Forschungsstiftung Analysis of methylated nucleic acid
MX2007006120A (es) 2004-11-23 2007-12-07 Adamas Pharmaceuticals Inc Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CN1299769C (zh) 2005-01-31 2007-02-14 中国医学科学院肿瘤医院肿瘤研究所 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途
EP2392675A1 (en) 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IFNG gene
CN101557823A (zh) * 2006-07-21 2009-10-14 加利福尼亚大学董事会 人内源性逆转录病毒多肽组合物和其使用方法
CN101646455A (zh) 2007-02-07 2010-02-10 财团法人阪大微生物病研究会 用于癌症的治疗剂
JP5579451B2 (ja) 2007-03-19 2014-08-27 グローブイミューン,インコーポレイテッド ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP2071334A1 (en) 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
ES2840750T3 (es) 2008-09-22 2021-07-07 Baylor College Medicine Métodos y composiciones para generar una respuesta inmune induciendo CD40 y adaptadores del receptor de reconocimiento de patrones
CN101885778B (zh) 2009-05-13 2013-10-16 中国疾病预防控制中心病毒病预防控制所 Hpv16型l2n120e7e6融合蛋白、基因、制备方法及用途
AU2010330364B2 (en) 2009-12-10 2016-05-19 Merck Patent Gmbh Pharmaceutical composition comprising oligopeptides, preferably cilengitide
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2011091319A2 (en) 2010-01-22 2011-07-28 Baylor Research Institute Dendritic cell vaccines
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
PT3023788T (pt) 2010-05-14 2020-05-18 Massachusetts Gen Hospital Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US20130266659A1 (en) 2010-06-02 2013-10-10 Neil P. Desai Methods of treating bladder cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
GB2487632B (en) 2011-01-14 2014-03-12 Genefirst Ltd Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
WO2012118821A2 (en) 2011-02-28 2012-09-07 Indiana University Research And Technology Corporation Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2013026027A1 (en) 2011-08-18 2013-02-21 Nestec S.A. Compositions and methods for detecting allelic variants
PT2755997T (pt) 2011-09-15 2018-10-30 Us Health Recetores de célula t que reconhecem mage restrito a hlaa1 ou hla-cw7
WO2013086464A1 (en) 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20130210014A1 (en) 2012-02-10 2013-08-15 Jeff Sharman Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients
AU2013221642A1 (en) 2012-02-15 2014-09-25 Janssen Diagnostics, Llc Highly sensitive method for detecting low frequency mutations
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
RU2018130123A (ru) 2012-05-03 2018-11-07 Фред Хатчинсон Кансэр Рисёч Сентер Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
JP2015533473A (ja) 2012-07-12 2015-11-26 ペルシミューン,インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
AU2013289970A1 (en) 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating CAR T cells
US20150191524A1 (en) 2012-07-27 2015-07-09 The Board Of Trustees Of The University Of Illinoi Engineering t cell receptors
WO2014056986A1 (en) 2012-10-11 2014-04-17 Universitat De Barcelona Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll)
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
WO2014150924A2 (en) 2013-03-15 2014-09-25 The Broad Institute, Inc. Accurate typing of hla through exome sequencing
US20160215042A1 (en) 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
WO2014197369A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
KR102429859B1 (ko) 2013-12-06 2022-08-04 더 브로드 인스티튜트, 인코퍼레이티드 신생물 백신을 위한 제형
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
BR112016016525A2 (pt) 2014-01-17 2017-08-08 Dbv Tech Método para indução de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+ em um indivíduo, método para melhorar uma condição em um indivíduo, e método para a produção de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+
WO2015130968A2 (en) 2014-02-27 2015-09-03 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US20170261508A1 (en) 2014-03-14 2017-09-14 The Trustees Of The University Of Pennsylvania Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US20160252511A1 (en) 2014-03-14 2016-09-01 Brian J. Czemiecki Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
DK3152569T3 (da) 2014-06-05 2020-08-17 Aimm Therapeutics Bv Midler og fremgangsmåder til bestemmelse af t-cellegenkendelse
US20170204140A1 (en) 2014-07-23 2017-07-20 Deakin University Antagonistic peptides
RS59710B1 (sr) 2014-08-07 2020-01-31 Pharmassist Ltd Metod određivanja mutacionog statusa pik3ca u uzorku
JP2017525760A (ja) * 2014-08-15 2017-09-07 ジェネクシン・インコーポレイテッドGenexine, Inc. 子宮頸癌を処置する方法
AU2015341926B2 (en) 2014-11-04 2018-09-27 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
CN107427567A (zh) * 2015-01-29 2017-12-01 宾夕法尼亚大学理事会 检查点抑制剂和疫苗组合物及其用于免疫疗法的用途
EP3265562A4 (en) 2015-03-05 2018-12-19 TrovaGene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids
JP2018512396A (ja) 2015-03-09 2018-05-17 キングス・カレッジ・ロンドン Th1応答を増強するためのrarアルファアゴニストを用いた併用療法
EP3075389A1 (en) 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
CN107709351A (zh) 2015-06-17 2018-02-16 株式会社医学生物学研究所 细胞毒性t细胞表位肽及其用途
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2017011710A2 (en) 2015-07-14 2017-01-19 Whitehead Institute For Biomedical Research Chromosome neighborhood structures and methods relating thereto
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
CN116121281A (zh) 2015-11-27 2023-05-16 卡瑟里克斯私人有限公司 经遗传修饰的细胞及其用途
MX2018009804A (es) 2016-02-12 2018-11-09 Nantomics Llc Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.
CN105693828A (zh) 2016-02-17 2016-06-22 深圳市中美康士生物科技有限公司 一种新的eb病毒ebna1表位肽及其在ebv相关疾病的诊断、治疗和预防中的用途
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
US20190307868A1 (en) 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
SG11201808831TA (en) 2016-04-15 2018-11-29 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
IL317855A (en) * 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2020000587A1 (zh) 2018-06-26 2020-01-02 龚浩 一种方便清洁的灭虫灯

Similar Documents

Publication Publication Date Title
JP2023106599A5 (enExample)
JP2020515640A5 (enExample)
CN109306005B (zh) 一种eb病毒特异性t细胞抗原受体及其应用
CN103483452B (zh) 双信号独立的嵌合抗原受体及其用途
JP2020537515A5 (enExample)
JP2008056679A5 (enExample)
CN110357953B (zh) 识别人巨细胞病毒pp65抗原的TCR
Murakami et al. HTLV-1 Tax enhances NF-κB2 expression and binds to the products p52 and p100, but does not suppress the inhibitory function of p100
CN103525775B (zh) 表达猪繁殖与呼吸综合征病毒游离受体重组腺病毒组及其制备与应用
JP2009506762A5 (enExample)
JP2015509707A5 (enExample)
JP2010518816A5 (enExample)
CN108085340A (zh) 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
WO2024140767A1 (zh) 用于预防或治疗hpv感染相关疾病的多核苷酸分子
JP2013518599A5 (enExample)
CN104829732A (zh) 一种重组蛋白及其在昆虫杆状病毒表达系统中的表达方法
JP2005512518A5 (enExample)
CN102633867A (zh) 抗原性改变的肠毒素c2突变体及编码基因与制备和应用
JPWO2020118094A5 (enExample)
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
CN118703545A (zh) 一种促进iNKT细胞精准再识别iNKT免疫逃逸型胰腺癌肿瘤细胞亚群的基因线路
CN114249811B (zh) 一种特异识别癌/睾丸抗原hca587/magec2的t细胞受体及其应用
CN105802975B (zh) 靶向her2阳性肿瘤的细胞制备物及其用途
JPWO2020112815A5 (enExample)